Ann: Imugene onCARlytics Doses First Patient in IV Combination, page-107

I think there may have been a change in treatment priorities, on the 15 May they updated the MAST trial site to include two different tumor types, Cholangiocarcinoma and Bile Duct Cancer.

I believe they have probably changed recruitment criteria to steer this type of patient into the trial? Probably because it was the first CR and he is more than likely still going strong. To me It makes sense to minimize time and costs to chase what disease you know it works in?

So maybe an explanation in the slowdown of Mast info, all a theory of course on my part, but could be one explanation for the lack of info and recruitment slow down?